Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Health
Biotech
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Wall Street reacts to Regeneron, Sanofi cholesterol drug study results

  • Adam Feuerstein
  • Damian Garde

By Adam Feuerstein and Damian Garde March 12, 2018

Reprints
Clogged Artery
APStock

Updated with stock prices.

It’s Monday, which means Wall Street is having a say about the results from a long-anticipated clinical trial of the cholesterol-lowering drug Praluent that were presented Saturday by Regeneron Pharmaceuticals and Sanofi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

‘Everybody has blood on their hands’: A decade-long battle…
‘Everybody has blood on their hands’: A decade-long battle over Medicare Advantage audits is coming to…
Inside the fall of star MIT scientist David Sabatini
Inside the fall of star MIT scientist David Sabatini
Pfizer is scolded by a U.K. trade group for…
Pfizer is scolded by a U.K. trade group for remarks its CEO made about vaccination
FDA may not always require post-approval trials to be…
FDA may not always require post-approval trials to be enrolled before accelerated approvals
Gene therapy can transform life for people with hemophilia.…
Gene therapy can transform life for people with hemophilia. But some patients don’t want it.
U.K. lawmakers urge Pfizer not to raise the price…
U.K. lawmakers urge Pfizer not to raise the price of its Covid-19 vaccine

Comments are closed.

Recommended Stories